AB
CYTK icon

Amalgamated Bank’s Cytokinetics CYTK Stock Holding History

Amalgamated Bank’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9M Buy
57,548
+4,747
+9% +$341K 0.03% 447
2026
Q1 		$3.48M Buy
52,801
+2,171
+4% +$138K 0.03% 564
2025
Q4 		$3.22M Sell
50,630
-1,783
-3% -$111K 0.02% 602
2025
Q3 		$2.88M Buy
52,413
+74
+0.1% +$3.05K 0.02% 663
2025
Q2 		$1.73M Sell
52,339
-226
-0.4% -$7.86K 0.01% 839
2025
Q1 		$2.11M Sell
52,565
-1,057
-2% -$48.6K 0.02% 750
2024
Q4 		$2.52M Hold
53,622
– – 0.02% 714
2024
Q3 		$2.83M Sell
53,622
-1,775
-3% -$98.9K 0.02% 665
2024
Q2 		$3M Buy
55,397
+4,099
+8% +$247K 0.03% 680
2024
Q1 		$3.6M Buy
51,298
+10,469
+26% +$810K 0.03% 633
2023
Q4 		$3.41M Sell
40,829
-1,024
-2% -$37.1K 0.03% 684
2023
Q3 		$1.23M Sell
41,853
-509
-1% -$17K 0.01% 1040
2023
Q2 		$1.38M Buy
42,362
+864
+2% +$32K 0.01% 1011
2023
Q1 		$1.46M Sell
41,498
-2,446
-6% -$99.8K 0.01% 977
2022
Q4 		$2.01M Buy
43,944
+83
+0.2% +$3.57K 0.02% 896
2022
Q3 		$2.13M Buy
43,861
+3,453
+9% +$166K 0.02% 817
2022
Q2 		$1.59M Buy
40,408
+489
+1% +$19.7K 0.01% 951
2022
Q1 		$1.47M Sell
39,919
-2,334
-6% -$82.9K 0.01% 1047
2021
Q4 		$1.93M Sell
42,253
-147
-0.3% -$5.67K 0.01% 961
2021
Q3 		$1.51M Buy
42,400
+4,628
+12% +$136K 0.01% 1055
2021
Q2 		$748K Buy
37,772
+28,175
+294% +$662K 0.01% 1428
2021
Q1 		$223K Sell
9,597
-824
-8% -$17.6K 0.01% 1432
2020
Q4 		$217K Buy
10,421
+290
+3% +$5.3K 0.01% 1405
2020
Q3 		$219K Buy
10,131
+1,151
+13% +$26.9K 0.01% 1280
2020
Q2 		$212K Sell
8,980
-1,369
-13% -$25.7K 0.01% 1272
2020
Q1 		$122K Sell
10,349
-415
-4% -$5.29K ﹤0.01% 1464
2019
Q4 		$114K Buy
10,764
+622
+6% +$6.39K ﹤0.01% 1720
2019
Q3 		$115K Sell
10,142
-117
-1% -$1.47K ﹤0.01% 1640
2019
Q2 		$115K Buy
+10,259
New +$98.9K ﹤0.01% 1681

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Amalgamated Bank's CYTK Position: Q2 2026 in Review

Amalgamated Bank increased its Cytokinetics (CYTK) stake by 9% in Q2 2026, buying an estimated $341K and bringing the position to 57,548 shares worth $4.9M. The position accounts for 0.03% of the portfolio, ranked #447.

Amalgamated Bank first reported a position in CYTK in Q2 2019 and has held it in 29 quarters since. 196 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Amalgamated Bank held 57,548 shares of Cytokinetics worth $4.9M as of Q2 2026.
  • Amalgamated Bank bought 4,747 Cytokinetics shares in Q2 2026, an estimated $341K.
  • Cytokinetics made up 0.03% of Amalgamated Bank's portfolio in Q2 2026, its #447 holding.
  • Amalgamated Bank first reported a position in Cytokinetics in Q2 2019 and has held it in 29 quarters since.
  • 196 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.